Menu Search
Equities

Charles River Laboratories International Inc

RV6:MUN

Charles River Laboratories International Inc

Actions
  • Price (EUR)184.70
  • Today's Change7.25 / 4.09%
  • Shares traded11.00
  • 1 Year change+5.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

  • Revenue in USD (TTM)4.06bn
  • Net income in USD413.08m
  • Incorporated1994
  • Employees20.00k
  • Location
    Charles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
  • Phone+1 (781) 222-6000
  • Fax+1 (978) 988-5665
  • Websitehttps://www.criver.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.